Part,  Chapter, Paragraph

1  III,    10.  2.  4|   molecular changes to clinical endpoints. Am J Pathol, 159:2249-2256.~ ~
2  III,    10.  4.  2|      with similar toxicological endpoints. However, there is a need
3  III,    10.  4.  2| intermediate effects when ideal endpoints are not accessible to measurements.
4  III,    10.  4.  5|      urban areas.~ ~Many health endpoints have been considered in
5  III,    10.  4.  5|      etc) are considered. These endpoints often escape formal epidemiological